Title and Organization:
Ms. Hilleman is Lead Director of Omada Health and a member of the Board of Directors and Audit Committee Chair of public and private companies including Novocure (Nasdaq: NVCR), an international oncology company delivering a novel device therapy for solid tumors called Tumor Treating Fields, SI-Bone (Nasdaq: SIBN), an international company commercializing minimally invasive treatments for sacroiliac joint disorders, Minerva Neurosciences (Nasdaq: NERV), a clinical stage company focused on innovative solutions for patients with central nervous system diseases, and the Reiter Affiliated Companies, the international farming arm of Driscolls Berries. Previously, Ms. Hilleman served as a Director and Audit Committee Chair of Xenoport as well as of two non-profit organizations.
Ms. Hilleman served as a public company CFO for 20 years, raising over one billion dollars in equity and debt financings including 5 successful initial public offerings and several M&A transactions. Her experience spans diverse industries, including biopharmaceutical, medical device, lab instrument and software, energy and agricultural companies.
Ms. Hilleman participated in the Medical Sciences program at Brown University and earned an M.B.A. from the Wharton School. She is a member of the 1999 class of the Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute and has been recognized by several annual Silicon Valley award programs for her contributions as a CFO and as a business leader.